Skip to main content

Table 2 Uni- and multivariate analysis of predictive factors for overall survival in patients undergoing surgical resection after neoadjuvant therapy

From: Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients

  Number Median survival (95% CI) p value by log-rank test p value by Cox proportional hazards Hazard ratio (95% CI)
Gender
 Male 119 32.7 (27.3–58.3)    
 Female 121 35.7 (26.9–40.6) 0.821   
Pre-neoadjuvant therapy CA19–9 value (U/ml)
  > 103 U/ml 147 28 (23.5–32.9)    1.711
  ≤ 103 U/ml 93 40 (33.2-) 0.001 0.010 (1.133–2.639)
Pre-neoadjuvant therapy tumor size (mm)
  > 27 116 29.3 (23.3–34.9)    1.517
  ≤ 27 124 36.1 (30.1–115.7) 0.015 0.040 (1.018–2.278)
Location
 Ph 160 32.9 (26.7–36.9)    
 Pbt 80 34.9 (27.3-) 0.325   
Neoadjuvant therapy
 Systematic chemotherapy 115 35.7 (30.7–58.3)    
 Chemoradiotherapy 125 30.2 (27.3–40.6) 0.550   
NCCN Resectability
 Resectable 132 38.7 (33.9–99.2)    1.471
 Borderline 108 24.8 (19.9–30.7) < 0.0001 0.063 (0.979–2.219)
RESICT
 Other than progressive disease 236 33.2 (29.3–38.7)    3.930
 Progressive disease 4 17.6 (12.8–18.7) 0.023 0.064 (0.912–11.740)
Duration of neoadjuvant therapy (day)
  > 69 109 35.7 (28.3–50)    
  ≤ 69 131 32.7 (24.9–38.7) 0.413   
Operative procedure
 Pancreaticoduodenectomy 160 32.9 (26.7–36.9)    
 Distal pancreatectomy 80 34.9 (27.3-) 0.325   
N classification
 1 130 23.9 (20.4–32.9)    1.905
 0 110 40 (32.7–99.2) < 0.0001 0.002 (1.276–2.875)
R status
 1 35 19.9 (17.5–30.7)    1.659
 0 205 35.9 (30.1–41.7) 0.002 0.045 (1.012–2.627)
Adjuvant therapy
 yes 205 32.9 (29.3–38.7)    
 no 35 28.6 (15.2–83.1) 0.360   
  1. NCCN National Comprehensive Cancer Network, RECIST response evaluation criteria in solid tumours